{"a":[{"_":"FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time","$":{"href":"/pharma/fda-rejects-hengrui-elevar-pd-1-liver-cancer-combo-3rd-time","hreflang":"en"}}]}
RegulatoryrejectedcamrelizumabrivoceranibNegative
AI Analysis
Summary
The FDA has rejected Hengrui Pharma and Elevar Therapeutics' camrelizumab and rivoceranib combination for liver cancer for the third time. This represents a significant regulatory setback for the companies' development program.
Outcome Details
Third FDA rejection of the PD-1 liver cancer combination
Importance:8/10
Sentiment:
-0.95
FDA rejectionOncologyCombination therapyRegulatory setback
Read the original article
Published by FiercePharma on July 10, 2026 10:34 AM